<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04591457</url>
  </required_header>
  <id_info>
    <org_study_id>IndonesiaU-03</org_study_id>
    <nct_id>NCT04591457</nct_id>
  </id_info>
  <brief_title>The Efficacy, Safety, and Immunogenicity Study Comparing an Insulin Glargine Biosimilar Sansulin Log-G to Lantus</brief_title>
  <official_title>The Efficacy, Safety, and Immunogenicity Study Comparing an Insulin Glargine Biosimilar Sansulin® Log-G With Its Reference Lantus® in Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indonesia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indonesia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label randomised multicenter clinical study to investigate efficacy, safety,&#xD;
      and immunogenicity of the drug products: Insulin Glargine biosimilar ® Log-G and its&#xD;
      reference Lantus® in type 2 diabetes mellitus patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sansulin® Log-G is an insulin glargine biosimilar. For a biosimilar, its efficacy, safety,&#xD;
      and immunogenicity should be compared head-to-head with its reference product in at least&#xD;
      non-inferiority study. Immunogenicity assessment should always be done because it is&#xD;
      influenced by so many factors, from nature of the drug substance until patient and disease&#xD;
      related factors. Moreover its consequences also vary considerably, from clinically irrelevant&#xD;
      to serious and life-threatening. Immunogenicity of a biosimilar should always be investigated&#xD;
      in humans, since animal data are usually not predictive of the immune response in humans.&#xD;
&#xD;
      Since blinding of study participants is likely unfeasible, at least anti-drug antibodies&#xD;
      should be determined in a blinded fashion. Since anti-insulin antibodies develop early, then&#xD;
      6 months duration of study is adequate.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2020</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in HbA1c level after 24 weeks of therapy compared to baseline value</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients</measure>
    <time_frame>24 weeks</time_frame>
    <description>Number of patients with HbA1c &lt; 7%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-insulin antibodies (AIAs)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in anti-insulin antibodies (AIAs) after 24 weeks of therapy compared to baseline value</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>FBG &amp; PPBG</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in FBG &amp; PPBG compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemia</measure>
    <time_frame>24 weeks</time_frame>
    <description>Incidence and severity of hypoglycemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight gain</measure>
    <time_frame>24 weeks</time_frame>
    <description>Incidence of weight gain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>24 weeks</time_frame>
    <description>Incidence and severity of adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Insulin Glargine Sansulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug product Insulin Glargine, Sansulin Log-G 100 IU/mL (PT. Sanbe Farma)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin Glargine Lantus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug product Insulin Glargine, Pen Injector [Lantus] 100 IU/mL (PT. Sanofi-Aventis)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Glargine Sansulin</intervention_name>
    <description>Insulin Glargine (Sansulin Log-G) once daily at individually adjusted dose</description>
    <arm_group_label>Insulin Glargine Sansulin</arm_group_label>
    <other_name>Sansulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Glargine Pen Injector [Lantus]</intervention_name>
    <description>Insulin Glargine (Lantus) once daily at individually adjusted dose</description>
    <arm_group_label>Insulin Glargine Lantus</arm_group_label>
    <other_name>Lantus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with DM type 2, age at least 18 years, both genders.&#xD;
&#xD;
          2. T2DM patients who have been diagnosed for &gt; 1 year, and have been treated with one&#xD;
             oral antidiabetic at stable doses for &gt; 3 months prior to screening, have BMI of 18.0&#xD;
             to 35.0 kg/m2 inclusive, and HbA1C of &gt; 7.0% and insulin-naive.&#xD;
&#xD;
          3. Patients who are cooperative, reliable, and agree to have regular injections of&#xD;
             insulin, and are willing to comply with protocol procedure (willing to sign the&#xD;
             informed consent).&#xD;
&#xD;
          4. Female patients with adequate protection from conception. Females of childbearing&#xD;
             potential must use a reliable method of birth control during the study (barrier-method&#xD;
             or IUD). Women with history of bilateral tubal ligation, or with total hysterectomy,&#xD;
             or who are 2 years postmenopausal are also eligible.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy (confirmed by a positive urine pregnancy test) or lactation.&#xD;
&#xD;
          2. History of severe hypoglycemia during the last year (blood glucose level &lt;50 mg/dl&#xD;
             with transient dysfunction of central nervous system without other apparent cause)&#xD;
&#xD;
          3. History of diabetic ketoacidosis &gt; 2x within the last year.&#xD;
&#xD;
          4. Having hyperglycemia hyperosmolar status (HHS)&#xD;
&#xD;
          5. Renal impairment (eGFR &lt; 30 mL/min).&#xD;
&#xD;
          6. An employee of the Investigator or the Sponsor.&#xD;
&#xD;
          7. Participating in another clinical study within the past 3 months.&#xD;
&#xD;
          8. Receiving any immunosuppressants, including corticosteroids or cytostatics within the&#xD;
             last year or during the study.&#xD;
&#xD;
          9. Receiving any drug or supplement with hypoglycemic activity (except oral&#xD;
             antidiabetics) within 4 weeks prior to screening and during the study.&#xD;
&#xD;
         10. Receiving any drug with hyperglycemic activity within 4 weeks prior to screening and&#xD;
             during the study (eg. second generation antipsychotics, corticosteroids, tacrolimus,&#xD;
             protease inhibitors).&#xD;
&#xD;
         11. Have undergone pancreatectomy or pancreas / islet cell transplant.&#xD;
&#xD;
         12. Mental disorder&#xD;
&#xD;
         13. Any malignancies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tri Juli Edi Tarigan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cipto Mangunkusumo General Hospital/Faculty of Medicine Universitas Indonesia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tri Juli Edi Tarigan, MD</last_name>
    <phone>62 813 1544 83293</phone>
    <email>tje_tar@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nida Amalina, PH</last_name>
    <phone>62 856 9703 6895</phone>
    <email>amalinanida@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Internal Medicine Cipto Mangunkusumo General Hospital, Faculty of Medicine Universitas Indonesia</name>
      <address>
        <city>Jakarta Pusat</city>
        <state>Jakarta</state>
        <zip>10520</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <contact>
      <last_name>Tri Juli Edi Tarigan, MD</last_name>
      <phone>+62 813 15 483 293</phone>
      <email>tje_tar@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Nida Amalina, PH</last_name>
      <phone>+62 856 9703 6895</phone>
      <email>amalinanida@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <results_reference>
    <citation>Knezevic I. Evaluation of similar biotherapeutic products (SBPs): scientific principles and their implementation. Biologicals. 2011 Sep;39(5):256-61. doi: 10.1016/j.biologicals.2011.08.008. Epub 2011 Sep 9. Review.</citation>
    <PMID>21907589</PMID>
  </results_reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 10, 2020</study_first_submitted>
  <study_first_submitted_qc>October 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>October 10, 2020</last_update_submitted>
  <last_update_submitted_qc>October 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indonesia University</investigator_affiliation>
    <investigator_full_name>Dr Tri Juli Edi Tarigan, SpPD-KEMD</investigator_full_name>
    <investigator_title>Endocrinologist, Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Insulin glargine biosimilar</keyword>
  <keyword>diabetes mellitus</keyword>
  <keyword>efficacy</keyword>
  <keyword>safety</keyword>
  <keyword>immunogenicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

